Angelita Habr-Gama
Overview
Explore the profile of Angelita Habr-Gama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
3496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez L, Sao Juliao G, Cerdan Santacruz C, Renehan A, Cano-Valderrama O, Beets G, et al.
J Clin Oncol
. 2024 Oct;
:JCO2400405.
PMID: 39467217
Purpose: Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete response (cCR). Nearly...
2.
El Sissy C, Kirilovsky A, Lagorce Pages C, Marliot F, Custers P, Dizdarevic E, et al.
J Clin Oncol
. 2023 Oct;
42(1):70-80.
PMID: 37788410
Purpose: No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance of the Immunoscore biopsy (IS) was...
3.
Fernandez L, Sao Juliao G, Renehan A, Beets G, Papoila A, Vailati B, et al.
Dis Colon Rectum
. 2023 Jul;
66(10):e1054-e1055.
PMID: 37493212
No abstract available.
4.
Sao Juliao G, Fernandez L, Vailati B, Habr-Gama A, Azevedo J, Santiago I, et al.
Dis Colon Rectum
. 2023 Jul;
67(1):73-81.
PMID: 37493198
Background: A proportion of rectal cancer patients who achieve a clinical complete response may develop local regrowth. Although salvage appears to provide appropriate local control, the risk of distant metastases...
5.
Habr-Gama A, Sao Juliao G, Ortega C, Vailati B, Araujo S, Jorge T, et al.
BMC Cancer
. 2023 Jun;
23(1):546.
PMID: 37316784
Background: Neoadjuvant chemoradiation(nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer. Advantages of this approach include improved local control after radical surgery but also the opportunity...
6.
Cerdan-Santacruz C, Sao Juliao G, Vailati B, Corbi L, Habr-Gama A, Perez R
J Clin Med
. 2023 Apr;
12(8).
PMID: 37109210
The administration of neoadjuvant chemoradiotherapy (nCRT) followed by total mesorrectal excision (TME) and selective use of adjuvant chemotherapy can still be considered the standard of care in locally advanced rectal...
7.
Fernandez L, Sao Juliao G, Renehan A, Beets G, Papoila A, Vailati B, et al.
Dis Colon Rectum
. 2022 Dec;
66(1):41-49.
PMID: 36515514
Background: Nearly 30% of patients with rectal cancer develop local regrowth after initial clinical complete response managed by watch and wait. These patients might be at higher risk for distant...
8.
Cerdan-Santacruz C, Vailati B, Sao Juliao G, Habr-Gama A, Perez R
Surg Oncol
. 2022 May;
43:101774.
PMID: 35491334
The current standard of care for the treatment of locally advanced rectal cancer includes neoadjuvant chemoradiation (nCRT) followed by total mesorrectal excision (TME). The observation of significant primary tumor response...
9.
Vailati B, Sao Juliao G, Habr-Gama A, Perez R
Surg Oncol Clin N Am
. 2022 Mar;
31(2):171-182.
PMID: 35351272
In recent decades, rectal cancer management has become increasingly challenging for multiple reasons. Proper imaging using dedicated magnetic resonance, standardization of total mesorectal excision, and incorporation of neoadjuvant treatment regimens...
10.
Kirilovsky A, El Sissy C, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pages C, et al.
Oncotarget
. 2022 Jan;
13:18-31.
PMID: 35018217
Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local...